Sickle Cell Disease & Thalassemia

At BIOOCUS International Treatment Center, we are proud to introduce Hemo-cel, a groundbreaking gene therapy offering new hope for patients suffering from sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT). Hemo-cel is designed to address the underlying cause of these conditions, offering a potential cure through a one-time treatment.

What is Hemo-cel?

Hemo-cel is an advanced therapy that uses the patient’s own hematopoietic stem and progenitor cells (HSPCs), which are genetically modified to produce healthy hemoglobin. By correcting the faulty gene responsible for the blood disorder, Hemo-cel can dramatically improve patients' lives, potentially eliminating the need for regular blood transfusions and offering a lifelong solution.

How Does Hemo-cel Work?

The treatment process begins by collecting HSPCs from the patient’s blood. These cells are then enhanced outside the body using a lentiviral vector that introduces a modified β-globin gene. Once the cells are ready, they are reinfused back into the patient, where they begin to generate healthy red blood cells capable of producing functional hemoglobin. This process restores the balance between α-globin and β-globin chains in the blood, effectively reducing the symptoms of anemia and allowing the patient to achieve transfusion independence.

Proven Results

Clinical trials of Hemo-cel have shown remarkable success:

• 100% of patients in the trial achieved successful bone marrow engraftment.
• Most patients became transfusion-independent within weeks after the therapy.
• One patient has been transfusion-free for nearly four years without any significant side effects.
• The therapy also helps alleviate iron overload, a common complication in TDT patients who undergo regular transfusions.

A Safer Alternative

Unlike traditional treatments like hematopoietic stem cell transplantation (HSCT), which requires a donor match and carries risks such as graft-versus-host disease (GVHD), Hemo-cel uses the patient’s own cells, avoiding these complications. This makes the treatment safer and more accessible to a wider range of patients, without the need for long-term immunosuppressive therapy.

Our Global Expansion

Having achieved significant success in China, we are now expanding Hemo-cel's availability globally. With clinical partnerships in Saudi Arabia, Thailand, Malaysia, and more, we are committed to making this innovative treatment accessible to patients worldwide.

A Future without Transfusions

Hemo-cel offers a promising future for those affected by SCD and beta-thalassemia. Imagine a life free from constant blood transfusions, with the potential for a permanent cure. At BIOOCUS, we are committed to making this vision a reality through cutting-edge gene therapy solutions like Hemo-cel.

Contact us today to learn more about how Hemo-cel can transform your treatment journey and offer a brighter, healthier future.